Performance · Recovery · Longevity

Shopping Cart (0)

Catalogue

Shop

Browse “Muscle/Performamnce, Recovery/Tissue, Weight Loss/Metabolic and Research Peptides“ and advanced wellness compounds. Prices are shown in South African Rand (ZAR).

Research peptides & wellness compounds

Select a product to view available quantities, specifications and regulatory status. Quantities, documentation and pricing are confirmed before dispatch.

Ipamorelin 5mg (UPA Platinum)

Category:
Muscle / GH / Performance
SKU:
TRW-IPA
Price:
R 400.00
{{variant.name}}:
{{opt.name}}
{{opt.value ? '' : opt.name}}
{{opt.value ? '' : opt.name}}
Description

TEST RUN WELLNESS IPAMORELIN 5 | Ipamorelin 5mg Self-Mix Vial

 

Ipamorelin 5 (Ipamorelin 5mg) – The safest and most selective Growth Hormone Releasing Peptide (GHRP). Boosts lean muscle, skin elasticity, and sleep quality without affecting appetite or cortisol. Self-mix vial. 

 

Product Overview

Ipamorelin 5 is an Ipamorelin 5mg self-mix vial. Ipamorelin is a synthetic pentapeptide that acts as a selective ghrelin mimetic, binding to the ghrelin receptor (GH secretagogue receptor, GHS-R1a) in the brain to selectively stimulate the release of growth hormone from the pituitary gland.

 

It belongs to the GHRP (growth hormone-releasing peptide) family, derived from GHRP-1 but lacking the central Ala-Trp dipeptide. Unlike other GH releasing peptides, Ipamorelin selectively stimulates GH release without significantly affecting appetite, cortisol, prolactin, or other pituitary hormones.

 

How Ipamorelin Works: Selective GHS-R1a Ghrelin Receptor Agonist

Ipamorelin is a selective agonist of the ghrelin/GHS receptor 1a (GHS-R1a), a G protein-coupled receptor. Activation of GHS-R1a initiates intracellular signaling cascades that stimulate growth hormone release from the anterior pituitary.

 

Primarily via activation of ghrelin receptors in GHRH-positive neurons in the hypothalamus, Ipamorelin stimulates GH release in a manner that closely mimics the body's natural pulsatile secretion pattern.

 

This selectivity is what distinguishes Ipamorelin from earlier-generation GHRPs — it produces clean, targeted GH release without the appetite stimulation associated with GHRP-6 or the cortisol and prolactin elevation seen with other secretagogues.

 

Body Recomposition Benefits

Ipamorelin stimulates endogenous growth hormone pulses, which in turn drive hepatic IGF-1 production. GH and IGF-1 are anabolic hormones tied to protein synthesis, tissue repair, and lipolysis.

 

Clinically reported benefits of Ipamorelin therapy include increased lean muscle mass, reduced body fat, improved recovery, deeper sleep, and enhanced skin elasticity.

 

Realistic expectations involve gradual, modest body-composition changes over months when combined with diet and exercise, rather than rapid weight loss.

 

Subtle shifts in body composition may appear, such as modest reductions in subcutaneous fat and improved muscle retention with adequate protein intake.

 

The body composition changes from Ipamorelin — particularly when stacked with CJC-1295 — are more in the range of 3–6% body fat reduction with concurrent lean mass maintenance or slight gain over 3–6 months.

 

Titration Protocol

Ipamorelin is administered via subcutaneous injection. The standard solo Ipamorelin dose is 100–300 mcg per injection, given subcutaneously one to three times per day, with the single most important dose taken at bedtime on an empty stomach to align with the body's natural nocturnal GH release. A typical starting point is 100 mcg once nightly.

 

A standard titration schedule is as follows:

· Weeks 1–2: 100 mcg once daily — starting dose, establishes baseline tolerability
· Weeks 3–4: 150 mcg once daily — first escalation
· Weeks 5–8: 200 mcg once daily — standard solo dose
· Weeks 9–12: 200–300 mcg once daily — advanced range; some protocols split into 2–3 daily injections

Injections should be administered 30–60 minutes before bedtime on an empty stomach.

 

Cycles typically run for 8–12 weeks, followed by a washout period before repeat cycling. Dose escalation should only proceed if the current dose is well tolerated.

 

Combination Therapy

Ipamorelin is most commonly used in combination with a GHRH analogue for synergistic GH release:

 

· CJC-1295 (no-DAC) + Ipamorelin: The most common GH secretagogue stack pairs the non-DAC version of CJC-1295 with Ipamorelin, typically at 100 mcg of each peptide per dose, injected subcutaneously once daily at bedtime on an empty stomach, five days per week.

 

CJC-1295 (no-DAC) provides rapid GHRH receptor activation while Ipamorelin triggers amplified GH pulses. The standard research-community stack is 100–200 mcg each, co-injected 1–3 times daily in a fasted window (pre-bed is the most common single pin).

 

· CJC-1295 with DAC + Ipamorelin: The DAC version of CJC-1295 is not typically combined with GHRPs due to risk of overstimulation from the sustained GH elevation. The no-DAC version is the preferred pairing.

 

· BPC-157: The combination of Ipamorelin with BPC-157 targets both GH-mediated tissue repair and localized healing. BPC-157's anti-inflammatory and healing properties complement Ipamorelin's GH/IGF-1-mediated repair mechanisms.

 

· Sermorelin + CJC-1295 + Ipamorelin: A triple GH protocol combining Sermorelin (GHRH analog), CJC-1295 with no DAC (modified GRF 1-29), and Ipamorelin (selective GHRP/ghrelin mimetic) at 100–300 mcg before bed.

 

All combination approaches should be pursued under professional medical supervision.

 

Clinical Trial Record

Ipamorelin was initially characterized in cell and animal models. The foundational 1998 study introduced it and showed selective growth hormone release in rat pituitary cells, rats, and swine.

 

A published human trial of Ipamorelin was a Phase 2 study in 114 bowel-surgery patients, which tested gut recovery and found no significant difference from placebo.

 

A randomized, placebo-controlled, dose escalation study characterized the pharmacokinetics and pharmacodynamics of Ipamorelin in 48 healthy male subjects, showing linear pharmacodynamic GH release dependent on Ipamorelin concentration.

 

Technical Specifications

· Product Name: Ipamorelin 5
· Peptide: Ipamorelin (GHRP, selective GHS-R1a agonist)
· Concentration: 5mg per vial
· Form: Self-mix multi-dose vial
· Reconstitution: Requires bacteriostatic water for reconstitution
· Administration: Subcutaneous injection, once daily at bedtime (fasted)
· Supplier: Test Run Wellness (Wellness.testrun)

 

 ⚕️  Important Medical Notice

Please consult your medical practitioner regarding your body requirements, as the dosing information provided contains guideline dosages. Ipamorelin 5 is intended for use under professional medical supervision.

Regulatory notice. Test Run Wellness is an independent supplier and is not the manufacturer of the products referenced. No product should be used without appropriate regulatory authorisation and professional medical oversight.